Menopause is ubiquitous in all those born with functioning ovaries and the majority experience symptoms. Most navigate menopause without the need for medical treatments but an important minority request treatment for these symptoms. Hot flushes and night sweats (vasomotor symptoms) are the most common indication for treatment. The safe and effective management of menopausal symptoms is a patient and clinician priority. Clinical guidelines from the UK National Institute for Health and Care Excellence (NICE) are amongst the most rigorous and well respected internationally. These guidelines are developed based on systematic reviews and independent analysis. Evidence interpretation is by clinicians and other health professionals directly involved in the care of menopausal women. The 2024 NICE guidelines update follows nearly 3 years of evidence synthesis and stakeholder consultation. The update has addressed the effects of menopausal hormone therapy (MHT) on CVD, stroke, breast cancer, ovarian cancer and endometrial cancer. New evidence is presented about MHT after early menopause (40-44 years) and on the management of genitourinary symptoms associated with menopause
Planned release is 7th November and a summary with clinical implications of the new guidelines will be presented.